01
Cash & equivalents increased 9.3%
Cash & equivalents changed +9.3% from the comparable as-filed period.
$41.2M→$45.1MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTAldeyra Therapeutics, Inc.'s latest supported as-filed period reports net income of -$5.5M, 44.2% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +9.3% from the comparable as-filed period.
Debt changed -100.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed +44.2% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ALDX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001341235-26-000010SEC ↗8-KJul 30, 2026Period Jul 28, 20260001193125-26-326337SEC ↗8-KJul 15, 2026Period Jul 14, 20260001193125-26-304880SEC ↗4Jun 11, 2026Period Jun 9, 20260001193125-26-267634SEC ↗4Jun 11, 2026Period Jun 9, 20260001193125-26-267629SEC ↗4Jun 11, 2026Period Jun 9, 20260001193125-26-267623SEC ↗4Jun 11, 2026Period Jun 9, 20260001193125-26-267611SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed +42.5% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Research & development changed -59.0% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Stock-based compensation changed +735.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-267605